Sanja Stevanović

Sanja Stevanović

Auto-generated profile, based on publicly available information

Sanja Stevanović

Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2015 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SSSanja Stevanović
Sanja Stevanović
LDLindsey M. Draper
Lindsey M. Draper
MLMichelle M. Langhan
Michelle M. Langhan
TCTracy E. Campbell
Tracy E. Campbell
MKMei Li Kwong
Mei Li Kwong
CHChristian S. Hinrichs
Christian S. Hinrichs
Purpose: Metastatic cervical cancer is a prototypical chemotherapy-refractory epithelial malignancy for which better treatments are needed. Adoptive T-cell therapy (ACT) is emerging as a promising cancer treatment, but its study in epithelial malignancies has been limited. This study was conducted to determine if ACT could mediate regression of metastatic cervical cancer. Patients and Methods: Patients enrolled onto this protocol were diagnosed with metastatic cervical cancer and had previously received platinum-based chemotherapy or chemoradiotherapy. Patients were treated with a single infusion of tumor-infiltrating T cells selected when possible for human papillomavirus (HPV) E6 and E7 reactivity (HPV-TILs). Cell infusion was preceded by lymphocyte-depleting chemotherapy and was followed by administration of aldesleukin. Results: Three of nine patients experienced objective tumor responses (two complete responses and one partial response). The two complete responses were ongoing 22 and 15 months after treatment, respectively. One partial response was 3 months in duration. The HPV reactivity of T cells in the infusion product (as measured by interferon gamma production, enzyme-linked immunospot, and CD137 upregulation assays) correlated positively with clinical response (P = .0238 for all three assays). In addition, the frequency of HPV-reactive T cells in peripheral blood 1 month after treatment was positively associated with clinical response (P = .0238). Conclusion: Durable, complete regression of metastatic cervical cancer can occur after a single infusion of HPV-TILs. Exploratory studies suggest a correlation between HPV reactivity of the infusion product and clinical response. Continued investigation of this therapy is warranted.

14 April 2017 in Science
Verified
Journal Article
Closed access
PDF file
SSSanja Stevanović
Sanja Stevanović
APAnna Pasetto
Anna Pasetto
SHSarah R. Helman
Sarah R. Helman
JGJared J. Gartner
Jared J. Gartner
TPTodd D. Prickett
Todd D. Prickett
CHChristian S. Hinrichs
Christian S. Hinrichs
Targeting nonviral antigens in viral-driven cancer: Adoptive cell transfer harnesses a patient's own T cells to destroy cancer. The strategy can successfully treat epithelial tumors driven by human papillomavirus (HPV), but it remains unclear why only some patients respond. Stevanović et al. examined the antitumor T cell response associated with HPV + cervical cancers that underwent complete regression. Unexpectedly, reactive T cells were not directed against virally associated antigens, but rather against cancer germline antigens or neoantigens not previously recognized by the immune system. These findings counter the widely held belief that T cell responses against viral antigens are responsible for therapeutic effects in HPV-driven cancers. Science , this issue p. 200

4 January 2019 in Science Immunology
Verified
Journal Article
Closed access
PDF file
MAMojgan Ahmadzadeh
Mojgan Ahmadzadeh
APAnna Pasetto
Anna Pasetto
LJLi Jia
Li Jia
DDDrew C. Deniger
Drew C. Deniger
SSSanja Stevanović
Sanja Stevanović
SRSteven A. Rosenberg
Steven A. Rosenberg
Intratumoral T reg cells are tumor/neoantigen reactive.

30 September 2015 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
LDLindsey M. Draper
Lindsey M. Draper
MKMei Li M. Kwong
Mei Li M. Kwong
AGAlena Gros
Alena Gros
SSSanja Stevanović
Sanja Stevanović
ETEric Tran
Eric Tran
CHChristian S. Hinrichs
Christian S. Hinrichs
Purpose: The E6 and E7 oncoproteins of HPV-associated epithelial cancers are in principle ideal immunotherapeutic targets, but evidence that T cells specific for these antigens can recognize and kill HPV+ tumor cells is limited. We sought to determine whether TCR gene engineered T cells directed against an HPV oncoprotein can successfully target HPV+ tumor cells. Experimental Design: T-cell responses against the HPV-16 oncoproteins were investigated in a patient with an ongoing 22-month disease-free interval after her second resection of distant metastatic anal cancer. T cells genetically engineered to express an oncoprotein-specific TCR from this patient's tumor-infiltrating T cells were tested for specific reactivity against HPV+ epithelial tumor cells. Results: We identified, from an excised metastatic anal cancer tumor, T cells that recognized an HLA-A*02:01–restricted epitope of HPV-16 E6. The frequency of the dominant T-cell clonotype from these cells was approximately 400-fold greater in the patient's tumor than in her peripheral blood. T cells genetically engineered to express the TCR from this clonotype displayed high avidity for an HLA-A*02:01–restricted epitope of HPV-16, and they showed specific recognition and killing of HPV-16+ cervical, and head and neck cancer cell lines. Conclusions: These findings demonstrate that HPV-16+ tumors can be targeted by E6-specific TCR gene engineered T cells, and they provide the foundation for a novel cellular therapy directed against HPV-16+ malignancies, including cervical, oropharyngeal, anal, vulvar, vaginal, and penile cancers. Clin Cancer Res; 21(19); 4431–9. ©2015 AACR.

12 September 2013 in Blood
Verified
Journal Article
Open access
PDF file
SSSanja Stevanović
Sanja Stevanović
CBCornelis A.M. Van Bergen
Cornelis A.M. Van Bergen
SLSimone A. P. van Luxemburg-Heijs
Simone A. P. van Luxemburg-Heijs
BZBoris van der Zouwen
Boris van der Zouwen
Ekaterina S. JordanovaEkaterina S. Jordanova
Ekaterina S. Jordanova
JFJ. H. Frederik Falkenburg
J. H. Frederik Falkenburg
Key Points: GVHD after HLA-DPB1–mismatched CD4+ DLI after TCD-alloSCT is mediated by allo-reactive HLA-DPB1–directed CD4+ T cells. Viral infections after TCD-alloSCT can induce HLA class II on nonhematopoietic tissues, making them targets for CD4+ T cells in GVHD.

1 June 2005 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
CVCorine C. Visser
Corine C. Visser
SSSanja Stevanović
Sanja Stevanović
LVL. Heleen Voorwinden
L. Heleen Voorwinden
LBLouis van Bloois
Louis van Bloois
PGPieter J. Gaillard
Pieter J. Gaillard
ABAlbertus G. de Boer
Albertus G. de Boer